Page last updated: 2024-10-16

carbon monoxide and Dermatoses

carbon monoxide has been researched along with Dermatoses in 8 studies

Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.

Research Excerpts

ExcerptRelevanceReference
"Patients with SSc meeting the ACR/EULAR systemic sclerosis classification criteria with diffuse cutaneous SSc (dcSSc) subset per LeRoy criteria, and a disease duration of less than or equal to 18 months will be randomized to placebo or riociguat 0."2.84RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. ( Allanore, Y; de Oliveira Pena, J; Denton, C; Distler, O; Khanna, D; Matucci-Cerinic, M; Pope, J, 2017)
"Carbon monoxide (CO) is an important gaseous signaling molecule."1.62Red Light-Triggered Intracellular Carbon Monoxide Release Enables Selective Eradication of MRSA Infection. ( Cheng, J; Gan, G; Gao, L; Hu, J; Shen, Z; Zhang, G, 2021)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19905 (62.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Cheng, J1
Gan, G1
Shen, Z1
Gao, L1
Zhang, G1
Hu, J1
Distler, O1
Pope, J1
Denton, C1
Allanore, Y1
Matucci-Cerinic, M1
de Oliveira Pena, J1
Khanna, D1
MIGNOLET, F1
ROBERTSON, EE1
Rahier, S1
Piérard-Franchimont, C1
Piérard, GE1
Gagnon, L1
Blouin, A1
Cormier, Y1
Rye, WA1
Bolot, JF1
Bernard, JP1
Wiesendanger, MT1
Biron, A1
Bertoye, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)[NCT02283762]Phase 2121 participants (Actual)Interventional2015-01-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted to Week 52

Negative change in FVC percent predicted indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52

InterventionFVC percent predicted (Mean)
Riociguat (Adempas, BAY63-2521)-2.376
Placebo-2.945

Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52

The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of SSc. A decrease in the mean change of mRSS shows mRSS improved. (NCT02283762)
Timeframe: Baseline to week 52

Interventionscore on a scale (Mean)
Riociguat (Adempas, BAY63-2521)-2.088
Placebo-0.769

Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score to Week 52

The HAQ-DI is a composite measure from which a 'Standard Disability Index' score can be computed to assess a patient's disability level. Generally, a score of 0-1 represents mild to moderate difficulty, 1-2 moderate to severe disability and 2-3 severe to very severe disability. The HAQ-DI comprises 20 items that assess patient abilities across 8 functional activities: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item is rated on a 4-point scale: 0=Without ANY difficulty, 1=With SOME difficulty, 2=With MUCH difficulty, 3=UNABLE to do. The 8 scores of the 8 sections are summed and divided by 8. In the event that one section is not completed by a subject then the summed score would be divided by 7. The final overall HAQ-DI score ranges from 0 to 3 and positive change indicates worse health-related quality of life (HRQoL). (NCT02283762)
Timeframe: Baseline to week 52

,
Interventionscore on a scale (Mean)
BaselineChange from baseline
Placebo0.6930.127
Riociguat (Adempas, BAY63-2521)0.8880.054

Change From Baseline in Patient's Global Assessment Score to Week 52

The patient's global assessments (a self-report) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the patient's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52

,
Interventionscore on a scale (Mean)
BaselineChange from baseline
Placebo3.770-0.022
Riociguat (Adempas, BAY63-2521)3.9330.689

Change From Baseline in Physician's Global Assessment Score to Week 52

The physician's global assessments (reported by the physician) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the physician's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52

,
Interventionscore on a scale (Mean)
BaselineChange from baseline
Placebo4.016-0.745
Riociguat (Adempas, BAY63-2521)4.333-0.067

CRISS (American College of Rheumatology Composite Response Index for Clinical Trials) at Week 52 Reported as Number of Participants With a CRISS Probability >=0.60 or <0.60 From Baseline to Week 52

CRISS forms a composite response index consisting of SSc-related organ involvement and the following five variables: mRSS, FVC percent predicted, physician's and patient's global assessments, and HAQ-DI score (from SHAQ patient-reported outcome). The resulting index is a 2-step process that captures clinically meaningful worsening of internal organ involvement and the core variables that show change. Patients for whom the predicted CRISS probability was ≥ 0.60 were considered improved, while patients for whom the predicted probability was < 0.60 were considered not improved. (NCT02283762)
Timeframe: Week 52

,
InterventionParticipants (Count of Participants)
CRISS probability ≥ 0.60CRISS probability < 0.60
Placebo1150
Riociguat (Adempas, BAY63-2521)1149

Reviews

1 review available for carbon monoxide and Dermatoses

ArticleYear
[The skin of tobacco smokers].
    Revue medicale de Liege, 1996, Volume: 51, Issue:9

    Topics: Aging; Carbon Monoxide; Humans; Irritants; Leukoplakia, Oral; Nicotine; Skin Diseases; Skin Physiolo

1996

Trials

1 trial available for carbon monoxide and Dermatoses

ArticleYear
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Respiratory medicine, 2017, Volume: 122 Suppl 1

    Topics: Carbon Monoxide; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Activators; Female; H

2017

Other Studies

6 other studies available for carbon monoxide and Dermatoses

ArticleYear
Red Light-Triggered Intracellular Carbon Monoxide Release Enables Selective Eradication of MRSA Infection.
    Angewandte Chemie (International ed. in English), 2021, 06-07, Volume: 60, Issue:24

    Topics: Animals; Anti-Bacterial Agents; Carbon Monoxide; Drug Liberation; Escherichia coli; Flavanones; Ligh

2021
Suggestion on the prevention of chronic carbon monoxide poisoning.
    Revue medicale de Liege, 1948, Mar-15, Volume: 3, Issue:6

    Topics: Carbon Monoxide; Humans; Occupational Diseases; Skin; Skin Diseases

1948
Skin lesions in organic brain disease.
    British medical journal, 1953, Feb-07, Volume: 1, Issue:4805

    Topics: Brain; Brain Diseases; Brain Neoplasms; Carbon Monoxide; Carbon Monoxide Poisoning; Cerebral Hemorrh

1953
Bronchocutaneous fistula in dogs: influence of fistula size and ventilatory mode on airleak.
    Critical care medicine, 1989, Volume: 17, Issue:12

    Topics: Animals; Bronchial Fistula; Carbon Monoxide; Dogs; Fistula; High-Frequency Jet Ventilation; Oxygen;

1989
Human responses to isocyanate exposure.
    Journal of occupational medicine. : official publication of the Industrial Medical Association, 1973, Volume: 15, Issue:3

    Topics: Aerosols; Animals; Carbon Monoxide; Cyanates; Environmental Exposure; Eye Diseases; Hot Temperature;

1973
[Study of carbon monoxide transfer in the course of prolonged hyperbaric oxygen therapy given at intermittent sessions].
    Le Poumon et le coeur, 1970, Volume: 26, Issue:9

    Topics: Adult; Aged; Apnea; Bone Diseases; Carbon Monoxide; Female; Humans; Hyperbaric Oxygenation; Lung; Ma

1970